Myonal acts by relaxing both skeletal muscles and vascular smooth muscles, and demonstrates a variety of effects such as reduction of myotonia, improvement of circulation, and suppression of the pain reflex. The drug inhibits the vicious circle of myotonia by decreasing pain, ischaemia, and hypertonia in skeletal muscles, thus alleviating stiffness and spasticity, and facilitating muscle movement.
Myonal also improves dizziness and tinnitus associated with cerebrovasculardisorders or cervical spondylosis.
Chemically and Mechanistically Related Drugs
Inaperisone, Silperisone, Tolperisone
Safety in children has not been established (insufficient clinical experience).
Use in the Elderly
Since the elderly often have a physiological hypofunction, it is advisable to take measures, such as reduction in dosage under careful supervision.
Study of Myonal versus tizanidine for treatment of chronic low back pain.
Many therapies exist for treatment of chronic low-back pain (LBP) including the use of muscle relaxant and analgesic drugs. The aim of this study was to compare efficacy and tolerability of Myonal and tizanidine in combination treatment with tramadol in chronic LBP.
Both associations assumed for one month, have shown effective for LBP at rest and with effort. Myonal /tramadol, reducing discontinuation and allowing a better adherence to the therapy, may be considered a viable option for the treatment of chronic LBP.
Myonal suffers from a very low bioavailability when taken orally, as a result of high first pass intestinal metabolism; a transdermal patch containing Myonal is currently in development in South Korea. This has shown promise, with the antispasmodic effect lasting over 24 hours, compared to one to two hours following oral administration.
Myonal is also under investigation as an antihypertensive agent, with promising results from trials on beagles.